Upadacitinib

Upadacitinib was discovered by AbbVie scientists, RINVOQ is a JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. In human leukocyte cellular assays, RINVOQ inhibited cytokine-induced STAT phosphorylation mediated by JAK1 and JAK1/JAK3 more potently than JAK2/JAK2 mediated STAT phosphorylation. Upadacitinib (RINVOQ) received FDA approval in 2019 for the treatment of moderate to severe RA.

Find 31 Related Holders

Beijing Beilu Pharmaceutical Co., Ltd.

China

API Registration Country

API Inactive

Founded in:

1992-09-05
Country:

China
Address:

No. 3, Shuiyuan West Road, Miyun District, Beijing
Tax NO.:

91110000102017145R
Registered Funds:

491.855896 yuan
Website:

Log in to view
Email:

Log in to view

Go to Page

Recommended Suppliers of Upadacitinib

Echemi Pharmaceutical

CN

1 YR

Contact Supplier
Dingwang Technology (Wuhan) Co., Ltd.

CN

1 YR

Contact Supplier
GIHI CHEMICALS CO.,LIMITED

CN

1 YR

Contact Supplier
Henan Lihao Chem Plant Limited

CN

1 YR

Contact Supplier
Shanghai Lonwin Chemical Co.,Ltd

CN

1 YR

Contact Supplier

View 70 Suppliers Request for Quotation

Trade Alert - Delivering the latest product trends and industry news straight to your inbox.
(We`ll never share your email address with a third-party.)

National-level Technology-based SME
China's Top 100 Industrial Digitalization Enterprises List
The Drafting Unit of the "Specification for Operation and Management of Self-build Cross-border E-commerce Website" of the CCPIT
High-Tech Enterprise

鲁ICP备16009155号-1 | Copyright@Qingdao ECHEMI Digital Technology Co., Ltd.



Feedback & Suggestions

Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.